Insights and trends in development of TEAD–YAP/TAZ inhibitors: a review of PCT patents (2022 to June 2025)
Over the past 3 years, there has been a marked increase in the number of PCT patents claiming structurally diverse TEAD - YAP/TAZ inhibitors, including filings by potentially new players. This trend highlights the growing recognition of the TEAD - YAP/TAZ axis as an attractive strategy for the development of new drugs, particularly for anti-cancer therapeutics.
Authors
- Fei Xiang (ORCID: https://orcid.org/0000-0001-5397-8481)
- Yu Zhong (ORCID: https://orcid.org/0000-0001-6902-2732)
- Te Fan
- Yan Zhang (ORCID: https://orcid.org/0000-0003-3957-8312)
- Aiping Xiao
Institutions
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Zhongshan Hospital (CN)
- Tang Du Hospital (CN)
- Zhuhai Institute of Advanced Technology (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Expert Opinion on Therapeutic Patents
- Published
- 2025-10-13
- DOI
- https://doi.org/10.1080/13543776.2025.2574611
- Citations
- 1
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 1.15